Compare Knight-Swift Transportation Holdings Inc. (KNX) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Knight-Swift Transportation Holdings Inc. vs Organon & Co. Common Stock — how do they compare? Knight-Swift Transportation Holdings Inc. trades at $63.21 (market cap $10.29B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Knight-Swift Transportation Holdings Inc. is far larger — about 2.9× Organon & Co. Common Stock's market cap, and Knight-Swift Transportation Holdings Inc. pays the higher dividend (1.27%). Which is the better fit depends on your goals — on Pluang, investors hold Knight-Swift Transportation Holdings Inc. for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| KNX | OGN | |
|---|---|---|
Market Cap | $10.29B | $3.61B |
Volume | 3,650,223 | 1,808,049 |
Sector | Industrials | Health |
52-Week High | $82.45 | $13.81 |
52-Week Low | $41.68 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $12.79B | $11.03B |
Dividend Yield | 1.27% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Knight-Swift Transportation (KNX) trades at $63.01, down 2.34% with bearish technical signals. The company reported mixed earnings with Q2 2026 beating estimates but Q4 2025 missing expectations. Revenue trends show modest growth to $7.7B in 2026, though net income margin compression to 0.55% raises concerns. Analyst consensus remains strongly bullish with 64% buy ratings and $85.75 price target, while technical indicators show selling pressure with support at $63.
The stock presents a divergence between strong Wall Street optimism and current technical weakness. Upside potential exists from truckload margin improvements and capacity-driven freight recovery, but risks include margin pressure, CEO stock sales, and broader transportation sector volatility. The upcoming Q3 2026 earnings report on October 21, 2026 will be critical for validating the bullish analyst thesis.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Knight-Swift Transportation Holdings Inc.
Knight-Swift provides truckload, less-than-truckload, logistics, and freight management services. It operates a large transportation network across North America.
Read more on KNX →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
